Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase II Study of Trastuzumab in Combination With Lapatinib (Cohort A) or Pertuzumab in Combination With Trastuzumab-emtansine (Cohort B) in Patients With HER2-positive Metastatic Colorectal Cancer: the HERACLES (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)Trial

NCT03225937 is registered in ClinicalTrials.gov with Fondazione del Piemonte per l'Oncologia as lead sponsor.

NCT NCT03225937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03225937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase II Study of Trastuzumab in Combination With Lapatinib (Cohort A) or Pertuzumab in Combination With Trastuzumab-emtansine (Cohort B) in Patients With HER2-positive Metastatic Colorectal Cancer: the HERACLES (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)Trial
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2012
Completion date
June 30, 2019
Enrollment
54 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer